July 2017

New Product - Ibrance

Ibrance (palbociclib) is a small molecule inhibitor of cyclin dependent kinases (CDK) 4 and 6. Testing of palbociclib in a panel of molecularly profiled breast cancer cell lines revealed high efficacy against luminal breast cancers, particularly estrogen receptor (ER) positive breast cancers. Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine based therapy; fulvestrant in patients who have received prior therapy. Ibrance is supplied as capsules containing 75 mg, 100 mg or 125 mg of palbociclib in packs of 21.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au